Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis

American Journal of Nephrology

Volumn 38, Issue 4, 2013, Pages 345-354

  Mindikoglu, Ayse L ^a   Weir, Matthew R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cirrhosis; Creatinine; Cystatin C; Hepatorenal syndrome; Renal dysfunction

Indexed keywords

BIOLOGICAL MARKER; CREATININE; CYSTATIN C;

ACUTE KIDNEY FAILURE; ASCITES; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DISEASE CLASSIFICATION; FOOT EDEMA; GLOMERULUS FILTRATION RATE; HUMAN; HYPERVOLEMIA; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; LIVER CIRRHOSIS; MODEL FOR END STAGE LIVER DISEASE SCORE; OLIGURIA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX DIFFERENCE; VASOCONSTRICTION;

BIOLOGICAL MARKERS; COMORBIDITY; CREATININE; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HEMODYNAMICS; HUMANS; LIVER CIRRHOSIS; PROGNOSIS; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX;

EID: 84885085944     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000355540     Document Type: Review

References (63)

1. Cholongitas E, Senzolo M, Patch D, Shaw S, O'Beirne J, Burroughs AK: Cirrhotics admitted to intensive care unit: the impact of acute renal failure on mortality. Eur J Gastroenterol Hepatol 2009; 21: 744-750.
2. Gines P: Pharmacological management of hepatorenal syndrome: lessons from non-responders. J Hepatol 2011; 55: 268-269.
3. Gluud LL, Christensen K, Christensen E, Krag A: Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51: 576-584.
4. Garcia-Tsao G, Parikh CR, Viola A: Acute kidney injury in cirrhosis. Hepatology 2008; 48: 2064-2077.
5. US Department of Health and Human Services: Organ Procurement and Transplantation Network data. http://optn.Transplant. Hrsa.Gov/latestdata/rptdata.Asp (accessed January 18, 2013).
6. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Scholmerich J: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis: international ascites club. Hepatology 1996; 23: 164-176.
7. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V: Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-1318.
8. Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, Rodes J, Gines P: Meld score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41: 1282-1289.
9. European Association for the Study of the Liver: EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.
10. Runyon BA: Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-2107.
11. Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, Angeli P, Moreau R, Davenport A, Jalan R, Ronco C, Genyk Y, Arroyo V: Working party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011; 60: 702-709.
12. Kew MC, Brunt PW, Varma RR, Hourigan KJ, Williams HS, Sherlock S: Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet 1971; 2: 504-510.
13. Lluch P, Mauricio MD, Vila JM, Segarra G, Medina P, Del Olmo JA, Rodrigo JM, Serra MA: Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp Biol Med (Maywood) 2006; 231: 70-75.
14. Nijveldt RJ, Teerlink T, Siroen MP, van Lambalgen AA, Rauwerda JA, van Leeuwen PA: The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr 2003; 22: 17-22.
15. Nijveldt RJ, Teerlink T, van Leeuwen PA: The asymmetrical dimethylarginine (ADMA)- multiple organ failure hypothesis. Clin Nutr 2003; 22: 99-104.
16. Nijveldt RJ, Teerlink T, Van Der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA, van Leeuwen PA: Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003; 22: 23-30.
17. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575.
18. Vallance P, Leone A, Calver A, Collier J, Moncada S: Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20(suppl 12):S60-S62.
19. Vallance P: Endothelial regulation of vascular tone. Postgrad Med J 1992; 68: 697-701.
20. Lluch P, Torondel B, Medina P, Segarra G, Del Olmo JA, Serra MA, Rodrigo JM: Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol 2004; 41: 55-59.
21. Siroen MP, van der Sijp JR, Teerlink T, van Schaik C, Nijveldt RJ, van Leeuwen PA: The human liver clears both asymmetric and symmetric dimethylarginine. Hepatology 2005; 41: 559-565.
22. Siroen MP, Wiest R, Richir MC, Teerlink T, Rauwerda JA, Drescher FT, Zorger N, van Leeuwen PA: Transjugular intrahepatic portosystemic shunt-placement increases arginine/asymmetric dimethylarginine ratio in cirrhotic patients. World J Gastroenterol 2008; 14: 7214-7219.
23. Richir MC, Bouwman RH, Teerlink T, Siroen MP, de Vries TP, van Leeuwen PA: The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function. JPEN J Parenter Enteral Nutr 2008; 32: 613-621.
24. Vizzutti F, Romanelli RG, Arena U, Rega L, Brogi M, Calabresi C, Masini E, Tarquini R, Zipoli M, Boddi V, Marra F, Laffi G, Pinzani M: ADMA correlates with portal pressure in patients with compensated cirrhosis. Eur J Clin Invest 2007; 37: 509-515.
25. Mookerjee RP, Malaki M, Davies NA, Hodges SJ, Dalton RN, Turner C, Sen S, Williams R, Leiper J, Vallance P, Jalan R: Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology 2007; 45: 62-71.
26. Koeppen BM, stanton BA: Glomerular filtration and renal blood flow; in Koeppen BM, Stanton BA (eds): Renal Physiology, ed 4. Philadelphia, Mosby, 2007, pp 31-46.
27. Rivolta R, Maggi A, Cazzaniga M, Castagnone D, Panzeri A, Solenghi D, Lorenzano E, di Palo FQ, Salerno F: Reduction of renal cortical blood flow assessed by Doppler in cirrhotic patients with refractory ascites. Hepatology 1998; 28: 1235-1240.
28. Wang Y, Liu LP, Bai WY, Wen SB, Dan HJ, Luan YY, Zeng MX, Hu B: Renal haemodynamics in patients with liver cirrhosis assessed by colour ultrasonography. J Int Med Res 2011; 39: 249-255.
29. Celebi H, Donder E, Celiker H: Renal blood flow detection with Doppler ultrasonography in patients with hepatic cirrhosis. Arch Intern Med 1997; 157: 564-566.
30. Mindikoglu AL, Dowling TC, Weir MR, Seliger SL, Christenson RH, Magder LS: Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology 2013, E-pub ahead of print.
31. Leslie SH, Johnston B, Ralli EP: Renal function as a factor in fluid retention in patients with cirrhosis of the liver. J Clin Invest 1951; 30: 1200-1207.
32. Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L: Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 1995; 122: 816-822.
33. Platt JF, Ellis JH, Rubin JM, Merion RM, Lucey MR: Renal duplex Doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology 1994; 20: 362-369.
34. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative Workgroup: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care 2004; 8:R204-R212.
35. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D: Symmetric dimethylarginine (SDMA) as endogenous marker of renal function - a meta-analysis. Nephrol Dial Transplant 2006; 21: 2446-2451.
36. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T: Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-1146.
37. Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, van Leeuwen PA: The clinical significance of asymmetric dimethylarginine. Annu Rev Nutr 2006; 26: 203-228.
38. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A, Acute Kidney Injury N: Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31.
39. Belcher JM, Garcia-Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, Coca SG, Parikh CR, TRIBE-AKI Consortium: Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology 2013; 57: 753-762.
40. de Carvalho JR, Villela-Nogueira CA, Luiz RR, Guzzo PL, da Silva Rosa JM, Rocha E, Moraes Coelho HS, de Mello Perez R: Acute kidney injury network criteria as a predictor of hospital mortality in cirrhotic patients with ascites. J Clin Gastroenterol 2012; 46:e21-e26.
41. Tsien CD, Rabie R, Wong F: Acute kidney injury in decompensated cirrhosis. Gut 2013; 62: 131-137.
42. Sherman DS, Fish DN, Teitelbaum I: Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 2003; 41: 269-278.
43. Papadakis MA, Arieff AI: Unpredictability of clinical evaluation of renal function in cirrhosis: prospective study. Am J Med 1987; 82: 945-952.
44. Cocchetto DM, Tschanz C, Bjornsson TD: Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance. Ther Drug Monit 1983; 5: 161-168.
45. Mindikoglu AL, Regev A, Seliger SL, Magder LS: Gender disparity in liver transplant waiting-list mortality: the importance of kidney function. Liver Transpl 2010; 16: 1147-1157.
46. Stevens LA, Coresh J, Greene T, Levey AS: Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483.
47. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB: Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004; 10: 301-309.
48. Skluzacek PA, Szewc RG, Nolan CR 3rd, Riley DJ, Lee S, Pergola PE: Prediction of GFR in liver transplant candidates. Am J Kidney Dis 2003; 42: 1169-1176.
49. Cholongitas E, Marelli L, Kerry A, Goodier DW, Nair D, Thomas M, Patch D, Burroughs AK: Female liver transplant recipients with the same GFR as male recipients have lower meld scores - a systematic bias. Am J Transplant 2007; 7: 685-692.
50. Mindikoglu AL, Raufman JP, Seliger SL, Howell CD, Magder LS: Simultaneous liverkidney versus liver transplantation alone in patients with end-stage liver disease and kidney dysfunction not on dialysis. Transplant Proc 2011; 43: 2669-2677.
51. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD 3rd, Zhang YL, Greene T, Levey AS: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51: 395-406.
52. Kottgen A, Selvin E, Stevens LA, Levey AS, Van Lente F, Coresh J: Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2008; 51: 385-394.
53. Demirtas S, Bozbas A, Akbay A, Yavuz Y, Karaca L: Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome. Clin Chim Acta 2001; 311: 81-89.
54. Gerbes AL, Gulberg V, Bilzer M, Vogeser M: Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002; 50: 106-110.
55. Randers E, Ivarsen P, Erlandsen EJ, Hansen EF, Aagaard NK, Bendtsen F, Vilstrup H: Plasma cystatin C as a marker of renal function in patients with liver cirrhosis. Scand J Clin Lab Invest 2002; 62: 129-134.
56. Ustundag Y, Samsar U, Acikgoz S, Cabuk M, Kiran S, Kulah E, Aydemir S: Analysis of glomerular filtration rate, serum cystatin C levels, and renal resistive index values in cirrhosis patients. Clin Chem Lab Med 2007; 45: 890-894.
57. Woitas RP, Stoffel-Wagner B, Flommersfeld S, Poege U, Schiedermaier P, Klehr HU, Spengler U, Bidlingmaier F, Sauerbruch T: Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis. Clin Chem 2000; 46: 712-715.
58. Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, Hostetter T, Levey AS, Panteghini M, Welch M, Eckfeldt JH: Recommendations for improving serum creatinine measurement: a report from the laboratory working group of the national kidney disease education program. Clin Chem 2006; 52: 5-18.
59. Daugherty NA, Hammond KB, Osberg IM: Bilirubin interference with the kinetic Jaffé method for serum creatinine. Clin Chem 1978; 24: 392-393.
60. Poge U, Gerhardt T, Stoffel-Wagner B, Klehr HU, Sauerbruch T, Woitas RP: Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients. Nephrol Dial Transplant 2006; 21: 660-664.
61. Hoek FJ, Kemperman FA, Krediet RT: A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003; 18: 2024-2031.
62. Larsson A, Malm J, Grubb A, Hansson LO: Calculation of glomerular filtration rate expressed in ml/min from plasma cystatin C values in mg/l. Scand J Clin Lab Invest 2004; 64: 25-30.
63. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS, CKD-EPI Investigators: Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20-29.